MabSelect™ PrismA is a protein A resin of which both the ligand and the base matrix have been optimized. The resin exhibits improved capacity over its predecessor MabSelect SuRe™ products, while maintaining purification performance. This application note demonstrates the binding capacity of MabSelect PrismA in comparison with its predecessor products for both polyclonal and monoclonal antibodies.
As the area of therapeutic monoclonal antibodies (mAbs) is growing rapidly, much effort is put on intensifying processes to increase productivity and cost‑efficiency. Ever‑increasing titers in upstream production demand increased efficiency in downstream purification. To prevent the initial downstream protein A capture step from becoming rate‑limiting for the manufacturing process, high efficiency of this step is crucial.
MabSelect PrismA is built on the heritage of alkaline‑stabilized MabSelect products. However, with enhanced properties of both the agarose base matrix and the protein A ligand, MabSelect PrismA provides a significantly increased capacity compared with its predecessor resins. In this work, the binding capacity and the purification performance of MabSelect PrismA in comparison with its predecessors are evaluated.